Dimoxamine is a memory adjuvant. Dimoxamine hydrochloride has been reported to facilitate the performance of naive rats in a massed trial shuttle box task. At doses that facilitated shuttle box responding, dimoxamine had no effect on unacclimated motor activity of rats nor on the rate of continuous avoidance responding by rats. Dimoxamine has a psychopharmacological profile that is different from other phenylalkylamines such as S-amphetamine and R-DOM. Dimoxamine may prove beneficial in the treatment of individuals having low or deteriorated levels of certain types of associative and psychomotor abilities. Dimoxamine substituted completely for LSD. Dimoxamine can be classified as a partial agonist of 5-HT receptors in sheep umbilical arteries.

Mazapertine (RWJ-37796) is an arylpiperazine antipsychotic with high affinity to dopamine D2 and D3, serotonin 5-HT1A and alpha 1A-adrenergic receptors. It was being studied in the treatment of schizophrenia.

Cefmepidium is a semisynthetic cephalosporin with broad antibacterial activity against penicillin-resistant strains.

Etorphine was the first potent opiate agonist employed primarily for use in non-domestic and wild species. Etorphine was 500 times as potent as morphine, with a very rapid onset and short duration of action. In morphine-dependent subjects, etorphine suppressed abstinence but for a shorter period than morphine. Etorphine is a full opiate agonist and binds to multiple opiate sites in the central nervous system. It is believed to produce its clinical effects through binding the µ-, δ-, and κ- opiate sites. It has a potent effect on depressing the respiratory centers of the CNS thus resulting in apnea being commonly seen in immobilized animals. Etorphine revolutionized the ability of biologists and veterinarians to safely capture and restrain many species that previously could not be handled. Etorphine is not currently commercially available due to lack of production by the manufacturer.

Fedotozine [(1R)-1-phenyl-1-[(3,4,5-trimethoxy) benzyloxymethyl]-N,N- dimethyl-n-propylamine, (2S,3S-tartrate], derived from the arylacetamide series, is an opioid drug which acts as a selective agonist for kappa(1a)-opioid receptor. Pharmacological studies have shown that fedotozine exerts a peripheral antinociceptive action, comparable with that of other kappa-agonists. Results of Phase III trials of fedotozine against irritable bowel syndrome and dyspepsia have ultimately been disappointing and was lack of efficacy in subsequent studies.

Moxipraquine is alkylaminopiperazinyl derivative patented by Wellcome Foundation Ltd. as antiparasitic agent effective against Trypanosoma cruzi. Moxipraquine was effective in suppressing parasitaemia but did not eradicate the infection from mice or guinea-pigs. Moxipraquine was less potent against mouse infections with strain Peru than it was against other strains of T. cruzi. In limited tests, moxipraquine was effective on experimental infections of Leishmania major, L. mexicana mexicana and L. brasiliensis panamensis but not L.b. brasiliensis. Significant foetal toxicity, observed experimentally in rats and rabbits, resulted in the termination of further trials.

Hydromorphinol, an opioid, and is a derivative of morphine and possesses similar properties: sedation, analgesia, and respiratory depression. Hydromorphinol is under the control according to US Single Convention 1961.

Proclonol is a cyclopropylmethanol derivative patented by Belgium pharmaceutical company Janssen Pharmaceutica N. V. as an arachnicide and fungicide. Tetranychus urticae in the adult stage on bean plants were killed within 3 days with a spray contg. 35 ppm. Proclonol, while all of the larval stage on strawberry leaves was killed by 62.5 ppm., and no eggs sprayed with 40 ppm. hatched. A suspension of 500 ppm. Proclonol used to dip strawberry leaves infested with Tarsonemus pallidus killed 96.2% of the mites.

FENYRIPOL is a skeletal muscle relaxant.

Volinanserin (MDL-100,907) is a highly selective 5-HT2A receptor antagonist. It is widely used in scientific research to investigate the function of the 5-HT2A receptor. Volinanserin is also being trialed as a potential antipsychotic, antidepressant and treatment for insomnia. Volinanserin (M-100907) was in phase III trials for chronic schizophrenia. In August 1999, development was discontinued for acute schizophrenia (schizoaffective disorder) on the basis of poor results. M-100907 is also active in animal models involving blockade of NMDA glutamatergic channel receptors, an effect known to resemble some behavioral symptoms of schizophrenia in man. M-100907 is also claimed in other patents for the treatment of thromboembolic disorders, for the treatment of various developmental neurological disorders such as autism and attention deficit hyperactivity disorder.